| ELM 2016—data update and new functionality of the eukaryotic linear motif resource H Dinkel, K Van Roey, S Michael, M Kumar, B Uyar, B Altenberg, ... Nucleic acids research 44 (D1), D294-D300, 2016 | 341 | 2016 |
| The PROTACtable genome M Schneider, CJ Radoux, A Hercules, D Ochoa, I Dunham, LP Zalmas, ... Nature reviews Drug discovery 20 (10), 789-797, 2021 | 175 | 2021 |
| In Silico Predictions of Endocrine Disruptors Properties M Schneider, JL Pons, G Labesse, W Bourguet Endocrinology 160 (11), 2709-2716, 2019 | 60 | 2019 |
| Towards accurate high-throughput ligand affinity prediction by exploiting structural ensembles, docking metrics and ligand similarity M Schneider, JL Pons, W Bourguet, G Labesse Bioinformatics 36 (1), 160-168, 2020 | 29 | 2020 |
| Structure-based and knowledge-informed design of B-Raf inhibitors devoid of deleterious PXR binding M Schneider, V Delfosse, M Gelin, M Grimaldi, M Granell, L Heriaud, ... Journal of medicinal chemistry 65 (2), 1552-1566, 2021 | 8 | 2021 |
| Exploring the conformational space of a receptor for drug design: an ERα case study M Schneider, JL Pons, G Labesse Journal of Molecular Graphics and Modelling 108, 107974, 2021 | 3 | 2021 |
| MM-PBSA and the importance of the dielectric constant for kinase drug design M Schneider, G Labesse | 1 | 2020 |
| N-(3-(5-(pyrimidin-4-yl) thiazol-4-yl) phenyl) sulfonamide compounds and their uses as braf inhibitors G Labesse, M Schneider, M Gelin, JA Guichou, M Cohen-Gonsaud, ... US Patent App. 17/782,485, 2023 | | 2023 |
| Chémoinformatique intégrative pour guider la conception des médicaments: application à la re-conception d’un inhibiteur clinique de kinase protéinique M Schneider Université Montpellier, 2019 | | 2019 |
| Solid-State NMR and FTIR Study of a Neuronal Calcium Sensor (NCS) Protein, Recoverin K Potvin-Fournier, A Picard-Lafond, M Schneider, G Valois-Paillard, ... Biophysical Journal 106 (2), 516a, 2014 | | 2014 |
